#United States #Baltimore #Scalp Cooling #Insurance Coverage #Paxman

Increasing Support for Scalp Cooling Legislation in the U.S.

As awareness of the impact of chemotherapy on patients rises, initiatives to mandate insurance coverage for scalp cooling therapy are gaining traction across the United States. Building on the early insurance mandates introduced in New York and Louisiana this January, eleven states are now pushing forward legislation that would ensure insurance coverage for this vital treatment.

Paxman, a global leader in scalp cooling technology, is at the forefront of these efforts, collaborating with lawmakers, patient advocates, and healthcare providers to create policies aimed at improving access to scalp cooling therapy, which has proven effective in managing the distressing side effects of cancer treatment.

Richard Paxman, the CEO of Paxman, emphasized the significance of insurance coverage in alleviating financial burdens for patients. He stated, "This progress aligns with our mission to minimize the suffering caused by cancer treatments."

Among the states taking action, Maryland has seen notable advancements. The House bill, HB 0393, has secured a resounding vote of 129-7, indicating strong bipartisan support, while its Senate counterpart, SB 0272, received unanimous approval. Both pieces of legislation reflect a comprehensive endorsement from healthcare professionals and patient advocates, who recognize the emotional and psychological toll of hair loss during chemotherapy.

Delegate LaToya Nkongolo, a key supporter of the Maryland legislation, remarked, "For many cancer patients, losing their hair can be one of the most visible and emotionally challenging aspects of chemotherapy. This legislation ensures that patients have access to a clinically validated treatment without the additional financial strain."

In California, where healthcare policies wield considerable influence, Assembly Bill 1682 is currently under review by the Assembly Health Committee. If passed, this mandate could significantly enhance patient access to scalp cooling therapy across the largest healthcare market in the nation.

Rhode Island is also making strides, with House Bill 7537, presented by Representative Karen Alzate, gaining momentum in the House Health and Human Services Committee. Support from patient advocates and healthcare professionals underscored the urgency of providing insurance coverage for these critical treatments.

Additionally, West Virginia has seen swift progress with House Bill 4089, also addressing scalp cooling therapy insurance coverage, passing the House of Delegates and gaining Senate approval with a vote of 33-1. This bill will soon be presented to Governor Patrick Morrisey for his consideration.

Moreover, there are pending bills in seven other states, including legislation in Kentucky, Massachusetts, New Jersey, Ohio, Pennsylvania, South Carolina, and Virginia, reflecting a nationwide recognition of the importance of addressing chemotherapy-related hair loss.

With the introduction of Category I CPT® codes for scalp cooling in January 2026, a standardized pathway for insurance reporting and reimbursement has been established. This crucial step supports wider adoption of scalp cooling systems by oncology practices and encourages further legislative efforts to expand patient access.

Paxman’s commitment to enhancing patient welfare resonates through these legislative efforts. Through concerted advocacy and collaboration with healthcare stakeholders, the push for scalp cooling therapy demonstrates a meaningful advancement in alleviating one of the many burdens faced by cancer patients.

For more information about Paxman’s Scalp Cooling System, visit Paxman Scalp Cooling.